Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Boston Scientific (BSX) Any Comments??? -- Ignore unavailable to you. Want to Upgrade?

To: Charles Broderick who wrote (707)	11/23/1999 11:03:00 AM
From: Lighthouse	Read Replies (3) \| Respond to of 798

Death of a Thousand Cuts? Consensus estimates for next year are drifting down. The company is now saying $1.20 in EPS for 2000 with 5%ish growth in revenues. To make numbers we need better margins. Gross margin has to tick upward or $1.20 is a no-go. DLJ is fooling with the tax rate to get to $1.20. Taking it down to 33%. Question for the thread: Is it reasonable to assume that BSX's tax rate will stay at a constant 33% in the outgoing years. Otherwise quality of earnings will be poor and the multiple will not expand. Cheers,